— Research, space, environment and discovery —
A new therapeutic, brensocatib, shows promise in treating non-cystic fibrosis (non-CF) bronchiectasis by inhibiting serine proteases, notably neutrophil elastase. The drug is expected to be most effective in patients with highly metabolically active neutrophils, which contribute to the disease's sym
The EGFR MET bispecific agent Rybrevant (Amivantamab) shows clear activity in EGFR-mutated lung cancer, but its significant toxicity profile has led to clinician hesitation for its frontline use. Despite demonstrating a survival benefit in the frontline MARIPOSA trial, experts note that its adoption
Experts anticipate that future combination therapies for ATTR-CM, including emerging monoclonal antibody-based clearance medicines, will require rigorous clinical trials to determine optimal patient selection. Given the high cost of current ATTR-CM treatments, these trials are essential to identify
Biotech-Führungskräfte zeigen gegensätzliche Ansichten zur Partnerschaftsrolle in der Medikamentenentwicklung. Desh, CEO von Protagonist Therapeutics, befürwortet Kooperationen. Er sieht darin externe Validierung, Finanzmittel und die Nutzung der Erfahrung großer Pharmaunternehmen, was das Marktpote
A debate among biotech leaders revealed sharply contrasting views on the role of partnerships in drug development. Desh, CEO of Protagonist Therapeutics, strongly advocates for collaborations, citing their importance for external validation, financial resources, and leveraging the extensive experien